<qa>  What is the name of the study that will include subjects with relapsed and reThis study will include subjects that have relapsed and refractory multiple myeloma RRMM after treatment with at least 3 prior antimyeloma therapies, including a proteasome inhibitor PI and an immunomodulatory drug IMiD or after development of double-refractoriness to a both a PI and an IMiD. 